
- Shares of Regencell Bioscience, a Hong Kong-based developer of traditional Chinese herbal treatments that it says can treat childhood ADHD and autism, more than tripled Monday. The stock soared more than 280% after a 38-for-1 stock split.
- The company, which has no revenue, is up roughly 46,000% in 2025.
- On Monday, one social media user on X remarked of the latest stock move: “for #CompleteBullsh__CompanyOfTheYear I nominate regencell.”